The Food and Drug Administration has approved a new MRI contrast agent developed by Nycomed Amersham for liver studies. The Buckinghamshire, U.K., company announced on Dec. 1 that Teslascan received the FDA's go-ahead. In addition to Nycomed Amersham's
The Food and Drug Administration has approved a new MRI contrast agent developed by Nycomed Amersham for liver studies. The Buckinghamshire, U.K., company announced on Dec. 1 that Teslascan received the FDA's go-ahead. In addition to Nycomed Amersham's marketing effort, Teslascan will be sold in the U.S. by Schering subsidiary Berlex Laboratories of Wayne, NJ. Berlex gained rights to Teslascan in 1992 in exchange for settling its claim that Nycomed's Omniscan MRI agent infringed on patents Schering holds for its Magnevist product (SCAN 8/26/92).
Berlex will market Teslascan under its own label and trade name, but the company has not yet determined what it will call the product, according to a Berlex spokesperson. Teslascan is not covered by Berlex's contrast media licensing agreement with Abbott Laboratories, which distributes Magnevist and x-ray contrast agent Ultravist
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.